Press Releases

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Feb 17, 2026

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 10, 2026

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Jan 21, 2026

Axogen Announces Proposed Public Offering of Common Stock

Jan 21, 2026

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Jan 12, 2026

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

Dec 17, 2025

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Nov 4, 2025

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 29, 2025

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

Oct 15, 2025